Literature DB >> 26685888

Which play a more important role in the development of large-sized prostates (≥80 ml), androgen receptors or oestrogen receptors? A comparative study.

Peng Zhang1, Wan-Li Hu2, Bei Cheng3, Yang-Jun Zeng4, Xing-Huan Wang4, Tong-Zu Liu4, Wei-Bing Zhang4.   

Abstract

OBJECTIVE: To compare the expression levels of androgen receptor (AR), oestrogen receptor α (ERα)and oestrogen receptor β (ERβ) in human prostate with various degrees of benign hyperplasia.
MATERIALS AND METHODS: Forty-five BPH patients undergoing transurethral plasmakinetic resection of the prostate were divided into three 15-people groups of participants with small (<40 ml), medium (40-80 ml) and large (>80 ml) prostates. Patient blood samples were collected for measuring serum oestradiol (E2), total testosterone (TT), follicle-stimulating and luteinizing hormone by radioimmunoassay. Postoperative prostate specimens were collected to detect AR, ERα and ERβ expression by immunoblotting and immunohistochemical staining.
RESULTS: There were significantly lower serum E2 levels in the patients with large prostates compared to the patients with small prostates (P < 0.05) and medium prostates (P < 0.01). A high TT and E2 serum ratio was observed in patients with large-sized prostates (P < 0.05), but there were no obvious differences in the serum TT levels between the three groups. Prostate AR expression in patients with large- (P < 0.05) and medium-sized prostates (P < 0.01) was high compared to patients with small-sized prostates. Prostate ERα expression in patients with large prostates was low compared to patients with small- and medium-sized prostates (P < 0.01). The prostate ERβ expression did not differ between the three groups (P > 0.05).
CONCLUSIONS: Increased AR and decreased ERα expression in the prostate suggested that AR might be more important than ERα in stimulating prostate proliferation in patients with large-sized prostates. Patients with small- and large-sized prostates might require different management procedures involving selective oestrogen receptor modulators and selective androgen receptor modulators, respectively.

Entities:  

Keywords:  Androgen receptor; Benign prostatic hyperplasia; Oestrogen receptor; Prostate volume

Mesh:

Substances:

Year:  2015        PMID: 26685888     DOI: 10.1007/s11255-015-1181-z

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  31 in total

Review 1.  Selective estrogen receptor modulators for BPH: new factors on the ground.

Authors:  M Garg; D Dalela; D Dalela; A Goel; M Kumar; G Gupta; S N Sankhwar
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-06-18       Impact factor: 5.554

Review 2.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

3.  Update on AUA guideline on the management of benign prostatic hyperplasia.

Authors:  Kevin T McVary; Claus G Roehrborn; Andrew L Avins; Michael J Barry; Reginald C Bruskewitz; Robert F Donnell; Harris E Foster; Chris M Gonzalez; Steven A Kaplan; David F Penson; James C Ulchaker; John T Wei
Journal:  J Urol       Date:  2011-03-21       Impact factor: 7.450

4.  Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.

Authors:  Tristan M Nicholson; Priyanka D Sehgal; Sally A Drew; Wei Huang; William A Ricke
Journal:  Differentiation       Date:  2013-06-20       Impact factor: 3.880

5.  Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern.

Authors:  E Enmark; M Pelto-Huikko; K Grandien; S Lagercrantz; J Lagercrantz; G Fried; M Nordenskjöld; J A Gustafsson
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

6.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer.

Authors:  Jennifer A Locke; Emma S Guns; Amy A Lubik; Hans H Adomat; Stephen C Hendy; Catherine A Wood; Susan L Ettinger; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

7.  Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.

Authors:  Steven A Kaplan; Weizhong He; William D Koltun; Jana Cummings; Tim Schneider; Allam Fakhoury
Journal:  Eur Urol       Date:  2012-07-17       Impact factor: 20.096

8.  Estrogen receptor-α is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia.

Authors:  Tristan M Nicholson; Michael A Moses; Kristen S Uchtmann; Kimberly P Keil; Dale E Bjorling; Chad M Vezina; Ronald W Wood; William A Ricke
Journal:  J Urol       Date:  2014-08-25       Impact factor: 7.450

9.  The role of dihydrotestosterone in benign prostatic hyperplasia.

Authors:  Culley Carson; Roger Rittmaster
Journal:  Urology       Date:  2003-04       Impact factor: 2.649

10.  Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells.

Authors:  H Nomura; H Kawashima; S Masaki; T Y Hosono; K Matsumura; S Tamada; T Tanaka; T Nakatani
Journal:  Prostate Cancer Prostatic Dis       Date:  2009-05-26       Impact factor: 5.554

View more
  4 in total

1.  Environmental estrogens have an impact on the ERs and their signaling in ER-responsive tissues and organs.

Authors:  Xu-Guang Guo
Journal:  Int Urol Nephrol       Date:  2016-03-22       Impact factor: 2.370

2.  Differential expression of androgen, estrogen, and progesterone receptors in benign prostatic hyperplasia.

Authors:  Lingmin Song; Wenhao Shen; Heng Zhang; Qiwu Wang; Yongquan Wang; Zhansong Zhou
Journal:  Bosn J Basic Med Sci       Date:  2016-06-13       Impact factor: 3.363

3.  Serotonin regulates prostate growth through androgen receptor modulation.

Authors:  Emanuel Carvalho-Dias; Alice Miranda; Olga Martinho; Paulo Mota; Ângela Costa; Cristina Nogueira-Silva; Rute S Moura; Natalia Alenina; Michael Bader; Riccardo Autorino; Estêvão Lima; Jorge Correia-Pinto
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

4.  Inhibitory effects of Pycnogenol®, a pine bark extract, in a rat model of testosterone propionate-induced benign prostatic hyperplasia.

Authors:  Je-Won Ko; So-Won Park; Na-Rae Shin; Woong-Il Kim; Jong-Choon Kim; In-Sik Shin; Dong-Ho Shin
Journal:  Lab Anim Res       Date:  2018-09-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.